Ionis Begins Dosing in Phase I/II Dravet Syndrome Study

ION337 has dosed its first patient in the Phase I/II ASCEND study for Dravet syndrome, an early milestone toward a potential disease-modifying therapy. While clinical efficacy is not yet demonstrated, the initiation of dosing is a positive development for the program’s progress and investor expectations.

Analysis

ION337 has dosed its first patient in the Phase I/II ASCEND study for Dravet syndrome, an early milestone toward a potential disease-modifying therapy. While clinical efficacy is not yet demonstrated, the initiation of dosing is a positive development for the program’s progress and investor expectations.